Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Recurrent Malignant Solid Neoplasm 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Malignant Neoplasms of Digestive Organs 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Liver Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1

Interventions

Sorafenib 42Bevacizumab 26Oxaliplatin 21Radiosurgery 19Gemcitabine 17Fluorouracil 15Hepatectomy 13lenvatinib 12Radiofrequency Ablation 11Nivolumab 11Cisplatin 11Radiotherapy 10Doxorubicin 10Capecitabine 10durvalumab 9Leucovorin 9Blood Specimen Collection 9atezolizumab 8Liver Transplantation 8Everolimus 7Electroporation 7pembrolizumab 6camrelizumab 6Sunitinib 6Immunohistochemistry 6Cryosurgery 6Carboplatin 6tremelimumab 5sintilimab 5apatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Liver Neoplasms × sapanisertib × Clear all
NCT02575339 2022-07-26

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Big Ten Cancer Research Consortium

Phase 1/2 Terminated
11 enrolled 15 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡